Skip to Content
Search Menu

An Update on New Treatments for Acute Myeloid Leukemia

AML is complex and composed of many genetic aberrations, making a “one treatment fits all” approach inadequate. This article examines the treatments that have been approved during the last 5 years and takes a look at treatments that are currently emerging and that may possibly be the next new treatments for AML.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32
Banu Aygun

REACH Study: Hydroxyurea’s 7-8 Year Impact on 600 African Children with Sickle Cell Anemia

/ Banu Aygun
ASH23ChildrenTreatment Play the Video 4:04

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
AMLASH23
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
AMLASH23 Play the Video 2:46

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

/ BestPractice Nordic
AMLEHA23

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Mark Levis
AMLEHA23 Play the Video 05:06

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

/ BestPractice Nordic
AMLCAR-TEHA23
Eunice Wang

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Eunice Wang
AMLASH22 Play the Video 10:56
Back to top